Reviva Pharmaceuticals' auditor Armanino declines re-appointment; audit committee seeks new firm

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Armanino LLP notified Reviva on July 18, 2023 it will not stand for re-appointment after Q3 2023 review.
Reason: Armanino is transitioning away from providing audit services to public companies.
Audit reports for FY2021 and FY2022 were unqualified; FY2022 included a going-concern paragraph.
No disagreements or reportable events occurred during the period through July 18, 2023.
Audit committee has begun search for a new independent registered public accountant for FY2023 audit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.